Cellectis SA ( (CLLS) ) has issued an announcement.
On March 31, 2025, Cellectis S.A. announced an update to its UCART pipeline, highlighting the progress of its and its licensees’ most advanced product candidates in clinical development. The update provides detailed information about the Phase 2 trials for ALLO-501A and IOV-4001, indicating the company’s ongoing commitment to advancing its clinical programs and potentially strengthening its position in the biotechnology industry.
More about Cellectis SA
Cellectis S.A. is a biotechnology company based in Paris, France, specializing in the development of gene-edited cell therapies. The company focuses on creating innovative solutions for cancer treatment through its proprietary gene-editing technologies.
YTD Price Performance: -29.83%
Average Trading Volume: 398,481
Technical Sentiment Signal: Buy
Current Market Cap: $94.81M
For a thorough assessment of CLLS stock, go to TipRanks’ Stock Analysis page.